Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

Trial Profile

Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FANTOM-II
  • Sponsors REVA Medical
  • Most Recent Events

    • 10 Nov 2017 Planned End Date changed from 1 Oct 2022 to 1 Mar 2023.
    • 10 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 03 Nov 2017 According to a REVA Medical media release, European CE Marking has been granted in April 2017, on the basis of data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top